Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

Therapeutic IL-12 has demonstrated the ability to reduce local immune suppression in preclinical models, but clinical development has been limited by severe inflammation-related adverse events with systemic administration. Here, we show that potent immunologic tumor control of established syngeneic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Youji, Robbins, Yvette, Yang, Xinping, Mydlarz, Wojciech K., Sowers, Anastasia, Mitchell, James B., Gulley, James L., Schlom, Jeffrey, Gameiro, Sofia R., Sievers, Cem, Allen, Clint T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983130/
https://www.ncbi.nlm.nih.gov/pubmed/35260537
http://dx.doi.org/10.1172/jci.insight.157448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983130/
https://www.ncbi.nlm.nih.gov/pubmed/35260537
http://dx.doi.org/10.1172/jci.insight.157448

Ejemplares similares